Novavax Inc (NVAX) reports a dramatic revenue increase and strategic collaborations, while navigating regulatory hurdles and ...

Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago. These figures are ...

Novavax (NVAX) closed the most recent trading day at ... At the same time, the Dow added 1.39%, and the tech-heavy Nasdaq gained 1.51%. Coming into today, shares of the vaccine maker had gained ...

(RTTNews) - Novavax, Inc. (NVAX) reported net income for the first ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

Novavax (NVAX) closed the most recent trading day at ... Elsewhere, the Dow saw a downswing of 2.48%, while the tech-heavy Nasdaq depreciated by 2.55%. Prior to today's trading, shares of the ...

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

Novavax (NVAX) closed the most recent trading day at ... Meanwhile, the Dow experienced a drop of 0.39%, and the technology-dominated Nasdaq saw a decrease of 0.05%. Shares of the vaccine maker ...

Novavax, Inc. (NASDAQ:NVAX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. Consensus estimates suggest investors could expect ...

$170,000 of NOVAVAX INC lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues related to COVID-19 vaccines ...

Novavax NVAX shares rallied 19.5% in the last trading session to close at $7.47. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session.

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of Novavax NVAX were down 19.6% on April 10 after the United States Health and Human Services (“HHS”) Secretary Robert F. Kennedy Jr., a well-known vaccine skeptic, raised concerns ...